Bank Julius Baer & Co. Ltd Zurich bought a new stake in Humana Inc. (NYSE:HUM – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 308 shares of the insurance provider’s stock, valued at approximately $86,000.
A number of other hedge funds and other institutional investors also recently modified their holdings of HUM. FPC Investment Advisory Inc. bought a new stake in shares of Humana in the 4th quarter valued at about $27,000. Centricity Wealth Management LLC purchased a new position in Humana during the 4th quarter valued at about $30,000. Ashton Thomas Securities LLC purchased a new position in Humana during the 3rd quarter valued at about $31,000. Atwood & Palmer Inc. increased its holdings in Humana by 64.5% during the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock valued at $39,000 after purchasing an additional 60 shares during the period. Finally, Kestra Investment Management LLC purchased a new position in Humana during the 4th quarter valued at about $49,000. Institutional investors own 92.38% of the company’s stock.
Insider Buying and Selling
In related news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.32% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
Check Out Our Latest Research Report on HUM
Humana Price Performance
NYSE HUM opened at $250.21 on Wednesday. The business’s fifty day moving average price is $271.67 and its 200-day moving average price is $281.65. The stock has a market capitalization of $30.19 billion, a price-to-earnings ratio of 25.15, a PEG ratio of 2.05 and a beta of 0.57. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $406.46.
Humana (NYSE:HUM – Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, equities analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.
Humana Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a $0.885 dividend. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a yield of 1.41%. Humana’s dividend payout ratio is currently 35.58%.
About Humana
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Articles
- Five stocks we like better than Humana
- Earnings Per Share Calculator: How to Calculate EPS
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- What is a Special Dividend?
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- The How and Why of Investing in Gold Stocks
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.